Hyperbaric Oxygen Therapy and Diabetic Neuropathy: What the Evidence Shows

Important: Hyperbaric oxygen therapy is not FDA-approved for diabetic neuropathy symptoms, and Medicare and commercial insurance do not cover it for this use. The approved, covered use is for qualifying diabetic foot wounds, which is a separate condition. Using HBOT for neuropathy itself is investigational, the evidence is preliminary and mixed, and all costs are out-of-pocket.

If you searched HBOT for neuropathy because of burning, numb, or tingling feet, the first thing to get straight is that it is not the same question as HBOT for a diabetic foot ulcer. The site covers wound healing in depth, and that use is FDA-approved and often covered. Treating the nerve symptoms themselves is a different and much less settled matter. People conflate the two constantly, and a clinic is happy to let the confusion ride, because one version gets reimbursed and the other gets paid in cash.

Wound Healing Versus Nerve Symptoms

Diabetes damages two things at once: circulation and nerves. The wound and the neuropathy are both downstream of that damage, but they are treated as distinct targets in medicine.

A diabetic foot ulcer is an open, non-healing wound. When it reaches a certain severity and has not improved with standard care, HBOT is an approved option that floods low-oxygen wound tissue with dissolved oxygen to support healing. That is the use described on the diabetic wounds page, and it has real evidence and a clear path to coverage.

Diabetic peripheral neuropathy is nerve damage. It shows up as numbness, tingling, burning pain, or loss of sensation, usually starting in the feet. You can have severe neuropathy without any wound at all. Using HBOT to try to relieve those nerve symptoms, rather than to close a wound, is off-label. The FDA has cleared HBOT for the wound, not for the nerve.

That distinction is not a technicality. It decides whether anyone will pay for the treatment.

Why HBOT Is Being Studied for Nerve Damage

Diabetic nerve damage is tied to the microvascular problems diabetes causes. The tiny blood vessels that feed peripheral nerves narrow and stiffen over time, and the nerves end up chronically short on oxygen. Oxidative stress and inflammation add to the injury.

The argument for HBOT targets that oxygen shortfall. By pressurizing the body and dissolving extra oxygen into the blood plasma, HBOT can raise the oxygen reaching tissue that normal circulation struggles to supply. The proposed effects include supporting starved nerve tissue and reducing the inflammation that contributes to nerve injury. The how HBOT works guide explains the underlying physiology in more detail.

This is a plausible rationale, not a demonstrated mechanism in human neuropathy. A theory about why something might work is the starting point for research, not a substitute for it.

What the Research Has Found

The honest summary is that the published results look favorable on their face but rest on low-quality trials, so they cannot carry much weight yet.

Weng et al. (2024) published a systematic review and meta-analysis in Medicine (Baltimore) pooling 14 randomized controlled trials with 1,323 patients who had diabetic peripheral neuropathy. The HBOT groups showed improvements in both motor and sensory nerve conduction velocity across the median, ulnar, peroneal, and tibial nerves, and a substantially higher treatment effective rate than standard therapy (PMID: 39252242).

That sounds like a clear win, and it is exactly the kind of headline a clinic will quote. The same authors, though, spelled out why it should not be read that way. Every one of the 14 trials was conducted in China, none of the studies used double-blinding, the methods for randomization and blinding were often not described, and there was significant heterogeneity between trials. They reported signs of publication bias in some outcomes. Their own conclusion was that these findings need validation through high-quality, rigorously designed trials before firmer conclusions can be drawn.

Pooling many small, unblinded, single-region trials can produce a strong-looking number that does not survive contact with a large, well-controlled study. Reading the favorable effect size without the authors’ caveats would misrepresent the strength of the evidence. The fair description is that the human evidence is preliminary and limited in quality, and the question is unsettled. Standard care for diabetic neuropathy remains glucose control plus the medications studied for nerve pain, such as duloxetine, pregabalin, and gabapentin, which have far more established evidence behind them.

Coverage: Why the Wound Distinction Matters for Your Bill

Medicare’s National Coverage Determination 20.29 covers HBOT for diabetic lower-extremity wounds when the patient has type I or type II diabetes, a wound classified Wagner Grade III or higher, and has failed an adequate course, at least 30 days, of standard wound care. Most commercial insurers follow similar criteria.

Read that list again. The covered indication is the wound. Diabetic neuropathy is not on it. If you have painful or numb feet but no qualifying wound, you do not meet the coverage criteria, and Medicare will not pay for HBOT to treat the neuropathy. The detail of how the diabetic-wound criteria work is covered in the guide for diabetic patients.

This is where the confusion gets expensive. A patient hears that HBOT is covered for diabetics, assumes that includes their nerve symptoms, and only learns otherwise after committing to a cash-pay course. Sessions typically run $250 to $450 each, rates change annually so verify current pricing with the facility’s billing team, and an off-label course can mean dozens of sessions. The total can reach well into five figures, paid entirely out of pocket. Because this is an off-label use, the off-label HBOT guide is worth reading before spending that money.

What HBOT Will Not Do

There is no good evidence that HBOT reverses established diabetic nerve damage or restores sensation that has already been lost. It is not a cure for neuropathy, and a clinic presenting it as one is moving past what the research supports.

HBOT also does not replace the foundation of neuropathy care. Tight blood sugar control slows the progression of nerve damage, and that, along with the standard medications and foot protection, has more evidence behind it than HBOT does for this use. Pursuing an investigational option should never mean letting glucose management or routine foot care slip. If you are weighing it, ask your endocrinologist or neurologist to review the current evidence with you rather than relying on a clinic that sells the treatment.

Frequently Asked Questions

Will insurance cover HBOT for my neuropathy symptoms? No. Neuropathy is not a covered indication. Coverage under Medicare’s NCD 20.29 applies to qualifying diabetic wounds, not to nerve pain or numbness on their own. If you have neuropathy without a qualifying wound, expect to pay out of pocket.

I have a diabetic foot wound and neuropathy. Does that change things? If your wound meets the Wagner Grade III or higher criteria and has failed 30 days of standard care, the wound may be a covered reason for HBOT. The coverage is for treating the wound, not the neuropathy. Your wound care team documents whether you qualify.

Does the research mean HBOT works for nerve pain? The pooled trials reported favorable nerve conduction and symptom results, but the authors themselves flagged that the studies were low quality, all from one country, and not double-blinded, and they called for better trials. The evidence is preliminary, not proof.

What has stronger evidence for diabetic neuropathy? Blood sugar control to slow nerve damage, and the medications studied for diabetic nerve pain such as duloxetine, pregabalin, and gabapentin, have more established evidence than HBOT for this use. Your care team is the right source for what fits your situation.

References

Weng, Q. et al. (2024). Efficacy and safety of hyperbaric oxygen therapy for diabetes peripheral neuropathy: A systematic review and meta-analysis. Medicine (Baltimore), 103(36). PMID: 39252242. https://pubmed.ncbi.nlm.nih.gov/39252242/

Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Hyperbaric Oxygen Therapy (20.29). https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=12

Browse every condition on the conditions hub. For the approved, covered use in diabetics, see the diabetic wounds page, and for another investigational nerve and brain topic, see the TBI and concussion page. To weigh any unproven use, read does HBOT work.

Medical Disclaimer: This page is for informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Hyperbaric oxygen therapy for diabetic neuropathy is investigational and not FDA-approved. Always consult a qualified healthcare provider before pursuing any medical treatment. This site does not establish a doctor-patient relationship.